The interplay between inflammation and oxidative stress in carcinogenesis

Current Molecular Medicine

Volumn 12, Issue 6, 2012, Pages 672-680

  Nowsheen, S ^a   Aziz, K ^b   Kryston, T B ^c   Ferguson, N F ^c   Georgakilas, A ^c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Carcinogenesis; DNA damage; Genomic instability; Inflammation; Oxidative stress; Tumor microenvironment

Indexed keywords

ALPHA TOCOPHEROL; BETA CATENIN; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CATALASE; CAVEOLIN 1; FERRITIN; GELATINASE A; GLUTATHIONE PEROXIDASE; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MACROPHAGE MIGRATION INHIBITION FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; RAC1 PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDOX EFFECTOR FACTOR 1; SCATTER FACTOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; DNA DAMAGE; DNA METHYLATION; DOUBLE STRANDED DNA BREAK; ENDOTHELIAL PROGENITOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXCISION REPAIR; FIBROBLAST; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; INFLAMMATION; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTAGENESIS; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PH; PHASE 3 CLINICAL TRIAL (TOPIC); STROMA; TISSUE PRESSURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; INFLAMMATION; MUTAGENESIS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; TUMOR MICROENVIRONMENT;

EID: 84862573920     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412800792642     Document Type: Article

References (103)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
3. Kryston TB, Georgiev A, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 2011; 711: 193-201.
4. Martin OA, Redon C, Nakamura AJ, Dickey JS, Georgakilas AG, Bonner WM. Systemic DNA damage related to cancer. Cancer Res 2011; 71: 3437-41.
5. Georgakilas AG. From chemistry of DNA damage to repair and biological significance. Comprehending the future. Mutat Res 2011; 711: 1-2.
6. Georgakilas AG. Detection of clustered DNA lesions: Biological and clinical applications. World J Biol Chem 2011; 2: 173-6.
7. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med 2010; 42: 161-70.
8. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010; 29: 243-8.
9. Klein TJ, Glazer PM. The tumor microenvironment and DNA repair. Semin Radiat Oncol 2010; 20: 282-7.
10. Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 2011; 19: 541-55.
11. Bonecchi R, Locati M, Mantovani A. Chemokines and cancer: A fatal attraction. Cancer Cell 2011; 19: 434-5.
12. Redon C, Dickey JS, Nakamura A, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc NatI Acad Sci USA 2010; 107: 17992-7.
13. Redon C, Dickey JS, Nakamura AJ, et al. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Cancer Res 2010; 70 (8 Supplement) 2287-8.
14. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009; 25: 30-8.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
16. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
17. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-65.
18. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4: 437-47.
19. Vaupel P, Kelleher DK, Hoeckel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001; 28: 29-35.
20. Bristow RG, Hill RP. Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8: 180-92.
21. Stewart RD, V.K. Y, Georgakilas AG, Koumenis C, Park JH, Carlson DJ. Effects of radiation quality and oxygen on clustered DNA lesions and cell death. Radiat Res. 2011; 175: DOI:10.1667/RR2663.1.
22. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's achilles' heel. Cancer Cell 2008; 13: 472-82.
23. Gravitz L. Chemoprevention: First line of defence. Nature 2011; 471: S5-S7.
24. Pavese J, Farmer R, Bergan R. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010; 29: 465-82.
25. Xu L, Ding Y, Catalona WJ, et al. MEK4 function, genistein treatment, and invasion of human prostate cancer cells. J Natl Cancer Inst 2009; 101: 1141-55.
26. Ma Q, Cavallin LE, Yan B, et al. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci USA 2009; 106: 8683-8.
27. Weydert CJ, Zhang Y, Sun W, et al. Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. Free Rad Biol Med 2008; 44: 856-67.
28. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010; 29: 351-78.
29. Jo M, Nishikawa T, Nakajima T, et al. Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroenterol 2011; 46: 809-21.
30. Ziech D, Franco R, Georgakilas AG, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chem Biol Interact 2010; 188: 334-9.
31. Georgakilas AG, Bennett PV, Wilson III DM, Sutherland BM. Processing of bistranded abasic DNA clusters in gammairradiated human hematopoietic cells. Nucleic Acids Res 2004; 32: 5609-20.
32. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res. 2010; 704: 152-9.
33. Pollycove M, Feinendegen LE. Radiation-induced versus endogenous DNA damage: possible effect of inducible protective responses in mitigating endogenous damage. Hum Exp Toxicol. 2003; 22: 290-306.
34. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9: 3256-76.
35. Hole PS, Pearn L, Tonks AJ, et al. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 2010; 115: 1238-46.
36. Aziz K, Nowsheen S, Georgakilas AG. Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways. Curr Mol Med 2010; 10: 626-39.
37. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-9.
38. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
39. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2: 53ra75.
40. Horton TM, Jenkins G, Pati D, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8: 2232-42.
41. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010; 9: 1775-87.
42. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70: 5457-64.
43. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-84.
44. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71: 2632-42.
45. Kelley MR, Cheng L, Foster R, et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001; 7: 824-30.
46. Yoon YJ, Chang HY, Ahn SH, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-6.
47. Seo Y, Kinsella TJ. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. Cancer Res 2009; 69: 7285-93.
48. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74.
49. Erdman SE, Poutahidis T. Cancer inflammation and regulatory T cells. Int J Cancer 2010; 127: 768-79.
50. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29: 285-93.
51. Kim S, Karin M. Role of TLR2-dependent inflammation in metastatic progression. Ann N Y Acad Sci 2011; 1217: 191-206.
52. Kowalewska M, Nowak R, Chechlinska M. Implications of cancer-associated systemic inflammation for biomarker studies. Biochim Biophys Acta 2010; 1806: 163-71.
53. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med 2010; 10: 369-73.
54. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 2010; 76: 1044-63.
55. Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci 2010; 14: 263-8.
56. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138: 2101-14 e5.
57. Kraaij MD, Savage NDL, van der Kooij SW, et al. Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc NatI Acad Sci USA 2010; 107: 17686-91.
58. Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem 2010; 340: 195-202.
59. Komatsu D, Kato M, Nakayama J, Miyagawa S, Kamata T. NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression. Oncogene 2008; 27: 4724-32.
60. Georgakilas AG. Processing of DNA damage clusters in human cells: Current status of knowledge. Mol Biosyst 2008; 4: 30-5.
61. Bartek J, Mistrik M, Bartkova J. Long-distance inflammatory and genotoxic impact of cancer in vivo. Proc NatI Acad Sci USA 2010; 107(42): 17861-2.
62. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000; 60: 6298-302.
63. Tudek B, Winczura A, Janik J, Siomek A, Foksinski M, Olinski R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am J Transl Res 2010; 2: 254-84.
64. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-81.
65. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 2011; 11: 9-20.
66. Lonkar P, Dedon PC. Reactive species and DNA damage in chronic inflammation: reconciling chemical mechanisms and biological fates. Int J Cancer 2011; 128: 1999-2009.
67. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-16.e1.
68. Piazuelo MB, Epplein M, Correa P. Gastric cancer: An infectious disease. Infect Dis Clin North Am 2010; 24: 853-69.
69. Georgakilas AG, Mosley W, Georgakila S, Zeich D, Panayiotidis MI. Viral-induced human carcinogenesis: an oxidative stress perspective. Mol Biosyst 2010; 6: 1162-72.
70. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle 2007; 6: 1030-4.
71. Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O. Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J 2007; 26: 987-97.
72. Fingerle-Rowson G, Petrenko O, Metz CN, et al. The p53- dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc NatI Acad Sci USA 2003; 100: 9354-9.
73. Brown L, Boswell S, Raj L, Lee SW. Transcriptional targets of p53 that regulate cellular proliferation. Crit Rev Eukaryot Gene Expr 2007; 17: 73-85.
74. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-30.
75. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883.
76. Lai LA, Paulson TG, Li X, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 2007; 46: 532-42.
77. Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD. Genomic instability in histologically normal breast tissues: implication for carcinogenesis. The Lancet 2004; 5: 753-8.
78. Nemec AA, Wallace SS, Sweasy JB. Variant base excision repair proteins: contributors to genomic instability. Semin Cancer Biol 2010; 20: 320-8.
79. Crespan E, Amoroso A, Maga G. DNA polymerases and mutagenesis in human cancers. Subcell Biochem 2009; 50: 165-88.
80. Prochownik EV. c-Myc: linking transformation and genomic instability. Curr Mol Med 2008; 8: 446-58.
81. Lindor NM, Jalal SM, VanDeWalker TJ, Cunningham JM, Dahl RJ, Thibodeau SN. Search for chromosome instability in lymphocytes with germ-line mutations in DNA mismatch repair genes. Cancer Genetics & Cytogenetics 1998; 104: 48-51.
82. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Research 1999; 59: 462-6.
83. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 2010; 7: 197-208.
84. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995; 87: 1114-25.
85. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 2010; 16: 5107-13.
86. Olschwang S. Germline mutation and genome instability. Eur J Cancer Prev 1999; 8 Suppl 1: S33-7.
87. Ziech D, Franco R, Pappa A, et al. The role of epigenetics in environmental and occupational carcinogenesis. Chem Biol Interact 2010; 188: 334-9.
88. Alemayehu A, Sebova K, Fridrichova I. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients. Genes Chromosomes Cancer 2008; 47: 906-14.
89. Brower V. Epigenetics: Unravelling the cancer code. Nature 2011; 471: S12-S3.
90. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
91. Toshiyuki Horikawa TYT-SSS-YLMF. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000; 89: 715-23.
92. Grek CL, Tew KD. Redox metabolism and malignancy. Curr Opin Pharmacol 2010; 10: 362-8.
93. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006; 25: 357-71.
94. Heo JS, Lee J-C. β-catenin mediates cyclic strain-stimulated cardiomyogenesis in mouse embryonic stem cells through ROS-dependent and integrin-mediated PI3K/Akt pathways. J Cell Biochem 2011; 1880-9.
95. Lee JY, Chang JW, Yang WS, et al. Albumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: effect of imatinib mesylate. Am J Physiol Renal Physiol 2011; 300: F1214-22.
96. Barnett P, Arnold RS, Mezencev R, Chung LW, Zayzafoon M, Odero-Marah V. Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells. Biochem Biophys Res Commun 2010; 404: 34-9.
97. Chang J, Jiang Z, Zhang H, Zhu H, Zhou SF, Yu X. NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. Int J Mol Med 2011; 8(3): 405-12.
98. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-9.
99. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
100. Ellis LM, Reardon DA. Cancer: The nuances of therapy. Nature 2009; 458: 290-2.
101. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
102. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331: 1612-6.
103. Jonietz E. Designing smarter cancer prevention trials. Nature 2011; 471: S20-S1.